Scarica l'app Stockscreener
103.11
5.17%
-5.62
Pre-mercato:
102.10
-1.01
-0.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Sei Investments Co. Purchases 677 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Short Interest Update - Defense World
PALVELLA THERAPEUTICS, INC. SEC 10-K Report - TradingView
Teacher Retirement System of Texas Boosts Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
HighTower Advisors LLC Boosts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Raymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Swiss National Bank Has $3.86 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand’s Second Quarter Financial Results to be Reported August 3rd - Business Wire
Victory Capital Management Inc. Buys 200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com - Defense World
US Bancorp DE Acquires 98 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Atria Investments Inc - Defense World
Bank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Smartleaf Asset Management LLC Buys 221 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Phar - GuruFocus
Mutual of America Capital Management LLC Has $307,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
CFO’s Major Stock Sale Shakes Up Ligand Pharma - TipRanks
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CFO Espinoza sells $575,148 in stock - Investing.com
Truist Financial Corp Lowers Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
LGND: First Steps into Cell & Gene Therapy - Research Tree
Ligand CEO and CFO Heading to Miami: Key Investor Access Points for LGND Shareholders - StockTitan
Ligand to Participate in March Investor Conferences - Yahoo Finance
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
Principal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth - TipRanks
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3%Should You Buy? - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings Results - MarketBeat
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating - Marketscreener.com
Ligand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Ligand Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
New York State Common Retirement Fund Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Ligand: Q4 Earnings Snapshot - mySA
Ligand Pharmaceuticals' Q4 Core Adjusted Net Income, Total Revenue Rise; 2025 Guidance Set - Marketscreener.com
Ligand Pharmaceuticals Incorporated Reaffirms the Earnings Guidance for the Year 2025 - Marketscreener.com
Ligand Pharma Slips To Loss In Q4; Confirms FY25 OutlookUpdate - Nasdaq
LIGAND PHARMACEUTICAL Earnings Results: $LGND Reports Quarterly Earnings - Nasdaq
Ligand Pharmaceuticals Q4 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Ligand: Q4 Earnings Snapshot -February 27, 2025 at 07:24 am EST - Marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals, Posts Q4 Revenue $42.8M, vs. FactSet Est of $39.0M - Marketscreener.com
Ligand Pharmaceuticals Inc Q4 Earnings Summary - Nasdaq
Ligand Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stake Reduced by Rhumbline Advisers - Defense World
Investor Network: Ligand Pharmaceuticals Incorporated to Host Earnings Call - ACCESS Newswire
Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need T - GuruFocus.com
Ligand Pharmaceuticals Inc (LGND) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Ligand Pharma Enters $75M Agreement with Castle Creek - TipRanks
Ligand Invests $75 Mln Royalty Financing In Castle Creek Biosciences - Nasdaq
Ligand backs Castle Creek's gene therapy with $75 million investment By Investing.com - Investing.com South Africa
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):